Navigation Links
Wayne State-licensed technology receives grant from the Foundation Fighting Blindness
Date:2/15/2012

DETROIT Technology to restore vision through the use of a component of green algae developed by a Wayne State University professor and scientific director of the Ligon Research Center of Vision at the Kresge Eye Institute has attracted additional funding for therapy development.

The Foundation Fighting Blindness announced a $250,000 grant from their affiliate, National Neurovision Research Institute, to RetroSense Therapeutics, LLC, a Michigan-based company. RetroSense signed a license agreement in 2011 for the novel gene-therapy approaches developed at Wayne State University by Zhuo-Hua Pan, Ph.D., professor of ophthalmology and anatomy & cell biology in the School of Medicine.

Pan's novel strategy focused on genetically converting light-insensitive inner retinal neurons into photosensitive cells, thus restoring light sensitivity to retinas that lack photoreceptors. Using a virus that delivers a photoreceptor gene from green algae called channelrhodopsin-2 (ChR2), he found that ChR2 made the inner retinal neurons light sensitive, and that this persisted for long periods in the neurons, ultimately leading to restored responses to light in the brain's visual cortex.

Pan, along with colleagues at Salus University in Pennsylvania, developed the breakthrough therapy and follow-on approaches that offer promise to people suffering with blindness caused by age-related macular degeneration (AMD) and retinitis pigmentosa (RP) retinal degenerative disorders that are currently incurable.

AMD is the leading cause of blindness in people older than 60, affecting more than 8 million in the United States. Worldwide, 500,000 individuals lose their eyesight annually to AMD, which is the result of progressive deterioration of photoreceptor cells in the macula, near the center of the retina.

RP is a genetically-determined eye disease caused by mutations in more than 100 different genes. An estimated 100,000 Americans have RP, which typically manifests as night blindness and progresses to tunnel vision and sometimes complete blindness.

"This field of research, known as optogenetics, is a very promising and creative approach to restoring vision in people with severe vision loss or complete blindness," said Stephen Rose, M.D., the foundation's chief research officer, in a news release. "RetroSense has outstanding technology, and it has achieved impressive results in lab studies. We are pleased to support the company in its effort to move the treatment into a clinical trial."

Rose said an advantage of optogenetic treatments is that because they work independently of genetic defects causing disease, they may work for a variety of retinal degenerations.

The foundation said the therapy developed by Pan has demonstrated restored vision in animal models with highly degenerated retinas. RetroSense Therapeutics is seeking U.S. Food and Drug Administration approval for a Phase I clinical trial.

Sean Ainsworth, founder and chief executive officer of RetroSense, licensed the technology from Wayne State University. He has said that Phase I clinical trials could begin in early 2013.


'/>"/>
Contact: Julie O'Connor
julie.oconnor@wayne.edu
313-577-8845
Wayne State University - Office of the Vice President for Research
Source:Eurekalert

Related biology news :

1. Wayne State University researchers model will target causes of everyday MS symptoms
2. Wayne State study finds soybean compounds enhances effects of cancer radiotherapy
3. Better CMT outcome measurement is Wayne State University physicians goal
4. Wayne State announces license agreement for breakthrough approaches to vision restoration
5. EPA grants help Wayne State researchers stave off Great Lakes environmental invaders
6. Wayne State start-up company NextCAT awarded nearly $500,000 from NSF for Phase II SBIR
7. Wayne State researcher discovers antibiotic useful for localized treatment of bone wear
8. Wayne State to study the role of vitamin D in African-Americans with high blood pressure
9. Wayne State University chosen as Michigans sole participant in EcoCAR 2
10. Soy increases effectiveness of radiation at killing lung cancer, Wayne State study shows
11. NextCAT secures license agreement for advanced biofuel technology from Wayne State
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... ... 10, 2017 , ... For the second time in three ... Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October ... US2020’s mission is to change the trajectory of STEM education in America by ...
(Date:10/10/2017)... ... 2017 , ... The Pittcon Program Committee is pleased to ... who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each award ... conference and exposition for laboratory science, which will be held February 26-March 1, ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which ... video EEG, in detecting generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). ...
(Date:10/6/2017)... , ... October 06, 2017 , ... ... a lunch discussion and webinar on INSIGhT, the first-ever adaptive clinical trial for ... Dana-Farber Cancer Institute. The event is free and open to the public, but ...
Breaking Biology Technology: